| Literature DB >> 32999931 |
Marco J Lobba1, Christof Fellmann2,3,4, Alan M Marmelstein1, Johnathan C Maza1, Elijah N Kissman1, Stephanie A Robinson1, Brett T Staahl2, Cole Urnes2, Rachel J Lew3, Casey S Mogilevsky1, Jennifer A Doudna1,2,3,5,6, Matthew B Francis1,7.
Abstract
The synthesis of protein-protein and protein-peptide conjugates is an important capability for producing vaccines, immunotherapeutics, and targeted delivery agents. Herein we show that the enzyme tyrosinase is capable of oxidizing exposed tyrosine residues into o-quinones that react rapidly with cysteine residues on target proteins. This coupling reaction occurs under mild aerobic conditions and has the rare ability to join full-size proteins in under 2 h. The utility of the approach is demonstrated for the attachment of cationic peptides to enhance the cellular delivery of CRISPR-Cas9 20-fold and for the coupling of reporter proteins to a cancer-targeting antibody fragment without loss of its cell-specific binding ability. The broad applicability of this technique provides a new building block approach for the synthesis of protein chimeras.Entities:
Year: 2020 PMID: 32999931 PMCID: PMC7517114 DOI: 10.1021/acscentsci.0c00940
Source DB: PubMed Journal: ACS Cent Sci ISSN: 2374-7943 Impact factor: 14.553
Figure 1Tyrosinase-mediated oxidative coupling reactions. (a) Phenols are oxidized by tyrosinase to yield o-quinone intermediates that couple with a variety of nucleophiles on biomolecules. This work explored the addition of cysteine thiolates (shown in red). (b) Structure of the MS2 viral capsid (PDB ID 2MS2), with 180 interior cysteine residues (N87C) indicated in red. Pores in the capsid shell allow the entry of peptides and small molecules. (c) Structure of α-endorphin, with the targeted tyrosine residue shown in blue. (d–f) Coupling reactions were screened using ESI-TOF MS, showing full modification of the MS2 N87C capsid without off-target oxidation. Reaction conditions: pH 6.5 phosphate buffer, RT, 30 min. Expected mass values: MS2 N87C [M + H]+ = 13719; MS2 N87C–N-ethylmaleimide (NEM) adduct [M + H]+ = 13844; MS2 N87C–endorphin o-hydroquinone product [M + H]+ = 15521.
Figure 2Structural analysis of thiol–o-quinone coupling products. (a) ROESY 1H NMR data (900 MHz) show a clear correlation between proton A and the corresponding signals from both the alkyl chain in N-acetylcysteamine (F) and the N-acetyltyrosine alkyl chain (E, G). (b) Energetics of the coupling reaction as estimated using DFT calculations. Geometry optimization and vibrational spectral calculations were conducted at the B3LYP-D3/6-31G** level, and final electronic energies were calculated at the ωB97M-V/6-311G++(3df,3pd) level. A CPCM solvation model was used in these calculations (see the Supporting Information for details and molecular coordinates). These data were combined to obtain the reported thermodynamic values. For comparison purposes, the reaction energies and equilibrium constants were estimated using this approach for the oxidation of the initial (c) aniline and (d) thiol coupling products with a methyl-substituted o-quinone.
Figure 3Synthesis of protein–peptide and protein–protein conjugates using thiol-directed enzymatic oxidative coupling reactions. (a, b) A superfolder GFP (sfGFP) thiol mutant (Y200C) was used as a protein component to evaluate peptide coupling reactions. All of the reactions were run for 30 min at RT and characterized using ESI-TOF MS. (c–e) A CRISPR-Cas9 variant with two C-terminal and four N-terminal nuclear localization sequences (Cas9-4NLS) was modified with peptide and protein coupling partners. Cas9 has two surface thiols (Cys 80 and Cys 574, red in the attached structure) in the native sequence. (c) ESI-TOF MS data indicated complete coupling at both sites with the α-endorphin peptide. The coupling reaction was successful even when the coupling partner was sfGFP bearing an exposed tyrosine residue near the N-terminus (MYGGS-GFP). All Cas9 couplings were run on ice for 1 h. (d) The site-specific DNA cleaving ability of the Cas9–peptide conjugate was unchanged relative to an untreated control. This was true when the preassembled ribonucleoprotein (RNP) was modified directly or when the RNA-free protein (apo-Cas9) was used for the modification reaction. In the latter case, the single guide RNA strand was added before the DNA cleavage experiment. (e) The Cas9–GFP conjugate retained site-specific DNA cleaving ability despite the high degree of added steric bulk.
Figure 4Evaluation of tyrosine–cysteine bioconjugates in cell culture assays. (a) Evaluation of modified CRISPR-Cas9 ribonucleoproteins (RNPs) for gene editing in neural progenitor cells. The assay measured the increase in fluorescent protein expression following successful editing at a tdTomato locus. Cas9 modified with two copies of the SV40 nuclear localization sequence (Cas9-2SV40) showed a 20-fold increase in editing efficiency compared with unmodified Cas9. Data were collected 72 h after treatment. Error bars show standard deviations of triplicates. (b) The coupling reaction was successful for the coupling of GFP Y200C to a HER2-binding scFv-GGY construct, as measured by ESI-TOF. The observed product mass was consistent with the linkage depicted in (c). (d) Flow cytometry analysis of SK-BR-3 (HER2+) and MDA-MB-468 (HER2−) breast cancer cells treated with the trastuzumab scFv–sfGFP construct showed HER2-specific cell binding. Gating and statistics are shown in Figure S18.